25 results about "Epithelial cancer" patented technology

The BTK-C isoform is expressed in human breast and prostate cancer cells and it plays a crucial role in epithelial cancer cell survival. BTK-C has a 34 amino acid extension to the n-terminus that facilitate it being palmitoylated on two cysteine residues. This modification localizes BTK-C closer to the cell membrane where it plays a role in improving cancer cell survival, as compared to BTK-A. BTK-C is not found to be expressed in healthy adult cells, whereas BTK-A is necessary for immune cell production. Disclosed herein are alternative kinases besides BTK having similar attributes, which present therapeutic opportunities for the treatment of cancers, especially for solid tumors.

Indivi dualized neoantigen vaccines, as well as methods for their use in subjects to treat urothelial orbladder cancer are provided. In some embodiments, individualized neoantigen vaccines are used with an immune checkpoint inhibitor and optionally enfortumab vedotin to treat a urothelial or bladder cancer after surgical resection. Prior to surgical resection, in some embodiments, the subject is administered a neoadjuvant therapy comprising an immune checkpoint inhibitor, individualized neoantigen vaccines, and, optionally, enfortumab vedotin.

The invention provides an application of an epidermal growth factor (EGF) in induction of apoptosis of an upper urinary tract epithelial carcinoma organ (UTUC), and belongs to the technical field of biomedicine. The invention relates to an application of an EGF (Epidermal Growth Factor) or EGFR (Epidermal Growth Factor Receptor) agonist in inducing The EGF induces apoptosis of the upper urinary tract epithelial cancer organoid by activating the STAT1-Caspase 3 pathway and up-regulating the expression level of the EGFR. In view of the fact that the upper urinary tract epithelium carcinoma organoid and the upper urinary tract epithelium carcinoma tissue are highly consistent in form and regulation mechanism, the technical scheme provided by the invention provides a new thought for the medicine for preventing and / or treating the upper urinary tract epithelium carcinoma.

The present invention belongs to the field of chemical medicine and discloses an EGFR proteolysis-targeted chimera, its preparation method, pharmaceutical composition, and application. The present invention provides an EGFR-degradable proteolysis-targeted chimera based on CP0371, a novel E3 ligase ligand with "molecular glue" functionality, and gefitinib, a target protein ligand. The EGFR proteolysis-targeted chimera prepared by the present invention can effectively induce EGFR degradation in cancer cell lines and has considerable bioavailability. It can be used to prepare EGFR inhibitors and can be used to form pharmaceutical compositions. It has a certain inhibitory effect on the proliferation of various tumor cells and is suitable for the development of cancer drugs for the treatment of colorectal cancer, lung cancer, esophageal cancer, glioblastoma, anal cancer, head and neck epithelial cancer, and other cancers.

The invention relates to a method for the treatment of cancer or adjuvating the treatment of cancer by exploiting the bidirectional tumor-nerve communication as novel pathway to induce an anticancer activity towards epithelial cancer cells using bioelectronic neuromodulation aimed at influencing the TME status.

The invention belongs to the field of marine natural pharmaceutical chemistry, and particularly provides a marine fungus-derived diterpenes diterpenoid compound as well as a preparation method and application thereof. According to the present invention, the diterpenes diterpenes compound is obtained from the marine fungus Penicillium brasilianum HBU-136, and the chemical structural formula of the marine fungus-derived diterpenes diterpenes compound is represented by the formula I, wherein the chemical structural formula of the marine fungus-derived diterpenes diterpenes compound is represented by the formula I, and the chemical structural formula of the marine fungus-derived diterpenes diterpenes compound is represented by the formula II; experiments prove that the compound has strong inhibitory activity on human gastric cancer cells (MGC-803, AGS and HGC-27), pulmonary epithelial cancer cells (A-549), liver cancer cells (HepG2) and colon cancer cells (SW-620), can be used as an antitumor drug, and has a wide application prospect.

The present invention relates to radiolabeled gemtuzumab ozogamicin antibodies and humanized versions conjugated with the radionuclide astatine 211 The antibody conjugates are used in radiotherapy for the treatment of urothelial cancer, including bladder cancer.

The present invention provides a method of assessing the risk of an individual to suffer from epithelial cancer, an analyzer therefor, and a kit thereof, the method comprising: measuring the content of a metabolite in a sample of the individual, the metabolite comprising urea nitrogen, creatinine, or a combination thereof; and comparing the contents of the metabolites of the negative control group and the sample, when the content of the metabolites of the sample is lower than the content of the metabolites of the negative control group, the individual is assessed to have the risk of suffering from the urinary epithelial cancer, and the kit comprises at least one reagent for identifying the metabolites in the sample of the individual so as to accurately assess the risk.

The invention belongs to the technical field of molecular biomedicine, and particularly relates to a urinary tract epithelial cell marker and application thereof in diagnosis of urinary tract epithelial cell carcinoma. The molecular marker is cytoplasm thyroid hormone binding protein CRYM, and an immunochemical staining experiment proves that the cytoplasm thyroid hormone binding protein CRYM has the potential to serve as a single immunomarker to be used for distinguishing normal urinary tract epithelial cells / reactive hyperplastic urinary tract epithelial cells and urinary tract epithelial cancer cells. Therefore, the kit plays a key identification role in histopathologic diagnosis or urine noninvasive screening of urothelial carcinoma, and provides important technical support for clinical noninvasive diagnosis.

Disclosed herein are antibody drug complexes comprising a drug unit coupled to an antibody capable of binding to TROP2 or an antigen-binding fragment thereof, and methods of using the antibody drug complexes. The methods of use include, but are not limited to, cancer treatment and detection. The antibody drug complexes disclosed herein can bind to specific cancer cell surfaces. Exemplary targets of the antibody drug complexes disclosed herein include epithelial cancers, such as lung cancer, breast cancer, head and neck cancer, esophageal cancer, gastric cancer, bladder cancer, pancreatic cancer, colorectal cancer, cervical cancer, endometrial cancer, ovarian cancer, laryngeal cancer, prostate cancer, thyroid cancer, and oral cancer.

This invention relates to compounds that are 4′-substituted analogues of the flavonol Fisetin. In particular, the invention relates to such compounds wherein the 4′ position on the B-ring is substituted with a ring deactivating group which has a para-Hammett constant greater than zero, and the use of these compounds in the treatment of cancer, including epithelial cancers.

Methylated gene marker panels are identified that can distinguish between biopsy and Pasteur smears of normal cervix from precancerous and malignant cervical cancer. In addition, a set of markers that differentiate between normal, low and high squamous intraepithelial lesions and cervical invasive squamous cell epithelial cancer allows for the selection of an appropriate treatment.

The invention discloses a urinary tract epithelial cancer detection reagent, a detection kit and application thereof. Specifically, the invention provides application of the reagent combination in preparation of the kit, and the reagent combination comprises a reagent for detecting the methylation level or state of a CpG island region comprising the following genes in a sample to be detected: (A) the CpG island region of the DMRTA2 gene is located in a chr1: 50421000-50421550 region; and (B) a CpG island region of any one gene selected from the following groups, or a combination thereof: (B1) the CpG island region of the TWIST1 gene is located in the chr7: 19117550-19118050 region; and (B2) the CpG island region of the VIM gene is located in the chr10: 17229200-17229700 region. The reagent or the kit provided by the invention can realize rapid and high-sensitivity non-invasive detection.

The present application aims to provide an epithelial cancer therapeutic drug with less side effects. To achieve the above object, the epithelial cancer therapeutic drug of the present application is characterized by containing at least one selected from the group consisting of an oxoacid, an oxoacid ion, and an oxoacid salt for treating or preventing an epithelial cancer.

A method for providing a prognosis for an epithelial cancer in a patient is disclosed. The method comprises: Detecting, in a biological sample obtained from the patient, a plurality of markers comprising at least one epithelial marker, at least one mesenchymal marker, at least one stromal cell type marker, and at least one morphological marker. Determining the prognosis for the epithelial cancer based on the detecting the plurality of markers.

The present invention relates to a culture media system that useful for the isolation and epigenetically stable propagation of normal stem cells in culture which are derived from columnar epithelial tissues and cancer stem cells from epithelial cancers. In certain embodiments, the culture system is a feeder-free system.

The present invention provides a compound of Formula I, a salt thereof, or a solvate thereof, as described herein, the composition is used for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative diseases, colorectal cancer, medulloblastoma, kidney cancer, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous carcinoma, gastrointestinal stromal tumor, glioma, mucus fibrosarcoma, smooth muscle sarcoma, neuroblastoma, synovial sarcoma, mesothelioma, and the like. Gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer and neurological cancer.

Provided is use of an antibody-drug conjugate targeting Her2 in combination with an immune checkpoint inhibitor such as PD-1 antibody or PD-L1 antibody, in the preparation of a medicine for treating patients with urothelial cancer, especially locally advanced or metastatic urothelial cancer. Compared to treatment with either of the two drugs alone, treatment with both in combination has a marked synergistic effect and significant therapeutic effect. In addition, the combination treatment had good efficacy for patients with low HER2 IHC expression (1+).

The application relates to the biomedical technology field, in particular to a nucleic acid combination product for detecting bladder cancer or urothelial cancer and application thereof. The nucleic acid combination product of the application adds a primer pair and a probe for detecting at least one of two auxiliary genes NID2 and PENK on the basis of a primer pair and a probe for detecting a single TWIST1 gene, improves the positive detection rate and accuracy of bladder cancer and urothelial cancer, and provides more possibilities for early detection of tumor diseases and treatment thereof.

The tumor stroma, which occupies a large part of the tumor mass, represents an attractive target for the delivery of diagnostic and therapeutic compounds. Here, particular emphasis is on a subset of stromal cells, called cancer-associated fibroblasts, which are present in more than 90% of epithelial cancers, including pancreatic, colon, and breast cancers. Cancer-associated fibroblasts are characterized by high expression of FAP, which is not detectable in normal adult tissues but is associated with poor prognosis in cancer patients. The present invention provides small molecule radiopharmaceuticals and imaging agents based on FAP-specific inhibitors.

The present disclosure relates to compounds that restore p53 activity and methods of using the compounds in the treatment of various conditions associated with loss of p53 activity, such as cancer, e.g., cancer. Such as sarcoma, epithelial cancer, head and neck cancer, hematological cancer, solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disease, myelodysplastic syndrome, myeloproliferative tumor, and the like; , non-small cell lung cancer, small cell lung cancer, kidney cancer, lung cancer, colon cancer, cervical cancer, and plasma cell tumor (myeloma). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Methods of isolating normal stem cells in culture derived from embryonic epithelial tissue and cancer stem cells derived from epithelial cancers and culture medium systems useful for epigenetically stable growth SOLUTION: A method for isolating stem cells from epithelial tissue, preferably columnar epithelial tissue, comprising: (I) culturing dissociated epithelial cells from a columnar epithelial tissue sample to form a stem cell colony; (ii) isolating single stem cells from the cell colony; and (iii) individually culturing the isolated single stem cells from step (ii) to form a culture of purified stem cell clones, wherein: Wherein each of the stem cell clones represents a clonal expansion of epithelial stem cells present in the columnar epithelial tissue sample, thereby isolating epithelial stem cells.SELECTED DRAWING: None

The present invention relates to a method of predicting the clinical outcome of a subject diagnosed with epithelial cancer, such as oral squamous cell carcinoma, and biomarkers for use in the method.

The invention discloses application of a reagent for inhibiting IGFBP5 in preparation of a medicine for treating malignant progression type recurrent bladder cancer, and relates to the technical field of biological medicine. The invention screens insulin-like growth factor binding protein 5 (IGFBP5) as a potential target of recurrent bladder cancer accompanied by malignant progression based on the recurrence evolution trajectory of bladder cancer. A further experiment shows that the target IGFBP5 can overcome the drug resistance of the target IGFBP5 to conventional chemotherapy and can also inhibit the malignant progression of the target IGFBP5. Therefore, the IGFBP5 can be used as a new therapeutic target of the recurrent bladder cancer accompanied by malignant progression, and a reagent for inhibiting the IGFBP5 can be applied to preparation of a medicine for treating the malignant progression type recurrent bladder cancer and possibly has important value in wider epithelial cancer.

The present invention relates to an in vitro method of classifying a patient that suffers from or is at risk of developing upper tract urothelial cancer, urothelial cancer or bladder cancer, said method comprising the steps of providing a liquid sample that has been obtained from a patient, and subjecting the sample to a first filtering step that withholds cells comprised in the sample yet lets smaller components like exosomes or macromolecules pass, so as to establish a cellular fraction and a first filtrate.